The Department of Defense is offering this grant to support the exploration of highly innovative, untested, and potentially groundbreaking concepts in prostate cancer research. This grant is specifically for fostering novel approaches where the emphasis is firmly on innovation, even if the potential impact may be difficult to predict at the initial stage. Applicants are strongly discouraged from submitting preliminary data, promoting truly fresh ideas. While human subject studies are permitted, they must be exempt or eligible for expedited review. A key feature of this grant is its blinded review process, ensuring impartiality by concealing the identities of the Principal Investigator, collaborators, and their institutions from peer and programmatic reviewers.
Opportunity ID: 157753
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-12-PCRP-EHDA |
| Funding Opportunity Title: | DoD Prostate Cancer Exploration-Hypothesis Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 25 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 22, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jun 20, 2012 |
| Current Closing Date for Applications: | Jun 20, 2012 |
| Archive Date: | Jul 20, 2012 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. Emphasis is on innovation; potential impact may be difficult to predict. Human subject studies are permitted provided the studies are exempt or eligible for expedited review. Preliminary data are strongly discouraged. Peer and programmatic reviewers are blinded to the identities of the PI, collaborators, and their institutions. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk: 301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 157753 Full Announcement-1 -> fy12 cdmrp gai final 12mar2012.pdf
Folder 157753 Full Announcement-1 -> pcrp_fy12_ehda_pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk: 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00109990 | Mar 22, 2012 | Jun 20, 2012 | View |
Package 1
Mandatory forms
157753 RR_SF424_1_2-1.2.pdf
157753 PerformanceSite_1_4-1.4.pdf
157753 RR_Budget-1.1.pdf
157753 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
157753 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
